Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive...(tol-Myers SquibbCompany Genentech Inc. a...),Health
| HOME >> MEDICINE >> TECHNOLOGY |
tol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements," including
statements relating to Lexicon's clinical development of LX6171 and the
potential therapeutic and commercial potential of LX6171. This press
release also contains forward-looking statements relating to Lexicon's
growth and future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other matters
that are not historical facts or information. All forward-looking
statements are based on management's current assumptions and expectations
and involve risks, uncertainties and other important factors, specifically
including those relating to Lexicon's ability to successfully conduct
clinical development of LX6171 and preclinical and clinical development of
its other potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent protection for
its discoveries and establish strategic alliances, as well as additional
factors relating to manufacturing, intellectual property rights, and the
therapeutic or commercial value of its drug candidates, that may cause
Lexicon's actual results to be materially different from any future results
expressed or implied by such forward-looking statements. Information
identifying such important factors is contained under "Factors Affecting
Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report
on Form 10-K for the year ended December 31, 2006, as filed with the
Securities and Exchange Commission. Lexicon undertakes no obligation to
update or revise any such forward-looking statements, whether as a result
of new information, future
'/>"/>
| SOURCE Lexicon Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine technology :
1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |